Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

  1. Mok, T.S.
  2. Cheng, Y.
  3. Zhou, X.
  4. Lee, K.H.
  5. Nakagawa, K.
  6. Niho, S.
  7. Chawla, A.
  8. Rosell, R.
  9. Corral, J.
  10. Migliorino, M.R.
  11. Pluzanski, A.
  12. Noonan, K.
  13. Tang, Y.
  14. Pastel, M.
  15. Wilner, K.D.
  16. Wu, Y.-L.
Revista:
Drugs

ISSN: 1179-1950,  0012-6667

Any de publicació: 2021

Volum: 81

Número: 2

Pàgines: 257-266

Tipus: Article

DOI: 10.1007/S40265-020-01441-6 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus